Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer TM, Santoro A, Lin CC, Garrido-Laguna I, Joerger M, Greil R, Spreafico A, Yau T, Goebeler ME, Hütter-Krönke ML, Perotti A, Juif PE, Lu D, Barys L, Cremasco V, Pelletier M, Evans H, Fabre C, Doi T. Bauer TM, et al. Among authors: hutter kronke ml. J Immunother Cancer. 2023 Nov 29;11(11):e007353. doi: 10.1136/jitc-2023-007353. J Immunother Cancer. 2023. PMID: 38030303 Free PMC article. Clinical Trial.
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
Abdul Razak AR, Bauer S, Suarez C, Lin CC, Quek R, Hütter-Krönke ML, Cubedo R, Ferretti S, Guerreiro N, Jullion A, Orlando EJ, Clementi G, Sand Dejmek J, Halilovic E, Fabre C, Blay JY, Italiano A. Abdul Razak AR, et al. Among authors: hutter kronke ml. Clin Cancer Res. 2022 Mar 15;28(6):1087-1097. doi: 10.1158/1078-0432.CCR-21-1291. Clin Cancer Res. 2022. PMID: 34921024 Clinical Trial.
PD-1 Blockade in Anaplastic Thyroid Carcinoma.
Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, Butler MO, Delord JP, Gelderblom H, Ascierto PA, Fasolo A, Führer D, Hütter-Krönke ML, Forde PM, Wrona A, Santoro A, Sadow PM, Szpakowski S, Wu H, Bostel G, Faris J, Cameron S, Varga A, Taylor M. Capdevila J, et al. Among authors: hutter kronke ml. J Clin Oncol. 2020 Aug 10;38(23):2620-2627. doi: 10.1200/JCO.19.02727. Epub 2020 May 4. J Clin Oncol. 2020. PMID: 32364844 Free PMC article. Clinical Trial.
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
Hütter-Krönke ML, Neagoie A, Blau IW, Wais V, Vuong L, Gantner A, Ahn J, Penack O, Schnell J, Nogai KA, Eberspächer B, Saadati M, Benner A, Bullinger L, Döhner H, Bunjes D, Sala E. Hütter-Krönke ML, et al. Front Immunol. 2023 May 3;14:1174289. doi: 10.3389/fimmu.2023.1174289. eCollection 2023. Front Immunol. 2023. PMID: 37207199 Free PMC article.
Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.
Hütter-Krönke ML, Fiedler W, Kündgen A, Krauter J, von Lilienfeld-Toal M, Döhner H, Schlenk RF. Hütter-Krönke ML, et al. Haematologica. 2019 Feb;104(2):e63-e64. doi: 10.3324/haematol.2018.199794. Epub 2018 Aug 31. Haematologica. 2019. PMID: 30171028 Free PMC article. No abstract available.
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.
Hütter-Krönke ML, Benner A, Döhner K, Krauter J, Weber D, Moessner M, Köhne CH, Horst HA, Schmidt-Wolf IG, Rummel M, Götze K, Koller E, Petzer AL, Salwender H, Fiedler W, Kirchen H, Haase D, Kremers S, Theobald M, Matzdorff AC, Ganser A, Döhner H, Schlenk RF. Hütter-Krönke ML, et al. Haematologica. 2016 Jul;101(7):839-45. doi: 10.3324/haematol.2015.141622. Epub 2016 Apr 1. Haematologica. 2016. PMID: 27036160 Free PMC article. Clinical Trial.
Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase.
Heudobler D, Luke F, Hahn J, Grube M, Schlosser P, Kremers S, Sudhoff T, Westermann J, Hutter-Kronke ML, Schlenk RF, Weber D, Paschka P, Zeman F, Dohner H, Herr W, Reichle A, Thomas S. Heudobler D, et al. Among authors: hutter kronke ml. Haematologica. 2024 Apr 1;109(4):1274-1278. doi: 10.3324/haematol.2023.283864. Haematologica. 2024. PMID: 37881883 Free PMC article. No abstract available.
Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment - Recommendations from an Expert Group from Austria, Germany, and Switzerland.
Matzdorff A, Alesci SR, Gebhart J, Holzhauer S, Hütter-Krönke ML, Kühne T, Meyer O, Ostermann H, Pabinger I, Rummel M, Sachs UJ, Stauch T, Trautmann-Grill K, Wörmann B. Matzdorff A, et al. Among authors: hutter kronke ml. Oncol Res Treat. 2023;46 Suppl 2:5-44. doi: 10.1159/000529662. Epub 2023 Feb 14. Oncol Res Treat. 2023. PMID: 36787705 Free article. Review. No abstract available.
[Expertenreport Immunthrombozytopenie - Aktuelle Diagnostik und Therapie].
Matzdorff A, Alesci SR, Gebhart J, Holzhauer S, Hütter-Krönke ML, Kühne T, Meyer O, Ostermann H, Pabinger I, Rummel M, Sachs UJ, Stauch T, Trautmann-Grill K, Wörmann B. Matzdorff A, et al. Among authors: hutter kronke ml. Oncol Res Treat. 2023;46 Suppl 1:7-53. doi: 10.1159/000528819. Epub 2022 Dec 26. Oncol Res Treat. 2023. PMID: 36572012 Free article. Review. German. No abstract available.